뉴스
22 DEC 2016 Alteogen clears phase 1 trial of Herceptin biosimilar in Canada
작성자
alteogen
작성일
2018-05-28 11:35
http://www.theinvestor.co.kr/view.php?ud=20161222000678
DISCLOSURE] Alteogen (196170) said on Dec. 22 that its biosimilar of Roche’s breast cancer antibody Herceptin has cleared phase 1 clinical trials in Canada.
The biosimilar is scheduled to enter phase 3 clinical trials in 2017.
By Jung Min-kyung (mkj1105@heraldcorp.com)
DISCLOSURE] Alteogen (196170) said on Dec. 22 that its biosimilar of Roche’s breast cancer antibody Herceptin has cleared phase 1 clinical trials in Canada.
The biosimilar is scheduled to enter phase 3 clinical trials in 2017.
By Jung Min-kyung (mkj1105@heraldcorp.com)